Sustained release injectable formulations of nevirapine for prevention of mother-to-child HIV transmission in breast-feeding populations

CHED 208

Rafaela Quintero1, Marc M. Baum, m.baum@oak-crest.org1, and Thomas J. Smith2. (1) Department of Chemistry, Oak Crest Institute of Science, 2275 E. Foothill Blvd., Pasadena, CA 91107, (2) Auritec Pharmaceuticals, 2275 E. Foothill Blvd., Pasadena, CA 91107
Each year 300,000 babies in Africa are infected with HIV through breast feeding. There is no clean water for bottle feeding. The non-nucleoside reverse transcriptase inhibitor nevirapine is currently instrumental in the prevention of perinatal HIV transmission. In order to extend the usefulness of nevirapine into breast feeding populations we have devised a polymer based sustained release formulation which can deliver prophylactic levels of drug for 6 weeks from a single injection. Such a formulation could be piggy-backed onto a program of accelerated DPT immunizations as used in the developing world. We will present details of the formulation, in vitro dissolution data and results of in vivo pharmacokinetic and safety studies in rats.
 

Undergraduate Research Poster Session: Biochemistry
2:30 PM-4:30 PM, Monday, 11 September 2006 Moscone Center -- Hall D, Poster

Division of Chemical Education

The 232nd ACS National Meeting, San Francisco, CA, September 10-14, 2006